Charles V. Clevenger
Affiliations: | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Charles Clevenger"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Byers HA, Brooks AN, Vangala JR, et al. (2023) Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer. Scientific Reports. 13: 15843 |
| Hathaway CA, Rice MS, Collins LC, et al. (2023) Prolactin levels and breast cancer risk by tumor expression of prolactin-related markers. Breast Cancer Research : Bcr. 25: 24 |
| Clevenger CV, Rui H. (2022) Breast cancer and prolactin - new mechanisms and models. Endocrinology |
| Woock AE, Grible JM, Olex AL, et al. (2021) Serine residues 726 and 780 have nonredundant roles regulating STAT5a activity in luminal breast cancer. Scientific Reports. 11: 13506 |
| Grible JM, Zot P, Olex AL, et al. (2021) The human intermediate prolactin receptor is a mammary proto-oncogene. Npj Breast Cancer. 7: 37 |
| Craig JM, Turner TH, Harrell JC, et al. (2021) Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer. Endocrinology |
| Hakim S, Craig JM, Koblinski JE, et al. (2020) Inhibition of the Activity of Cyclophilin A Impedes Prolactin Receptor-Mediated Signaling, Mammary Tumorigenesis, and Metastases. Iscience. 23: 101581 |
| Woock AE, Grible JM, Zot P, et al. (2020) SAT-139 STAT5A Regulation by Serine Phosphorylation in Breast Cancer Journal of the Endocrine Society. 4 |
| Grible JM, Zot P, Harrell JC, et al. (2020) SAT-130 The Intermediate Prolactin Receptor Is a Breast Cancer Oncogene Journal of the Endocrine Society. 4 |
| Adashek JJ, Szeto C, Sanborn JZ, et al. (2020) Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities. Journal of Clinical Oncology. 38: 3576-3576 |